Diamondback Energy, Inc. (NASDAQ:FANG) shares fell -3.22% in last trading session and ended the day at $73.85. FANG Gross Margin is 72.40% and its has a return on assets of -8.60%. Diamondback Energy, Inc. (NASDAQ:FANG) quarterly performance is 9.72%.
EastGroup Properties Inc. (NYSE:EGP) ended the last trading day at $57.30. Company weekly volatility is calculated as 2.24% and price to cash ratio as 6192.22. EastGroup Properties Inc. (NYSE:EGP) showed a weekly performance of -1.56%.
Eastgroup Properties (NYSE: EGP) declared a quarterly dividend of $0.60 per share, or $2.4 annualized. The dividend will be payable on December 31, 2015, to stockholders of record on December 4, 2015, with an ex-dividend date of December 2, 2015.
On 07 December, Attunity, Ltd. (NASDAQ:ATTU) shares fell -2.90% and was closed at $13.06. ATTU EPS growth in last 5 year was 9.40%. Attunity, Ltd. (NASDAQ:ATTU) year to date (YTD) performance is 21.49%.
Attunity Ltd. (NASDAQ: ATTU), announced that its 2015 Annual General Meeting of Shareholders will be held on Wednesday, December 30, 2015, at 10:00 a.m. (Israel time), at the Attunity offices located at 16 Atir Yeda Street, Atir Yeda Industrial Park, Kfar Saba, Israel. The record date for the meeting is November 24, 2015.
Aratana Therapeutics, Inc. (NASDAQ:PETX) shares fell -6.76% in last trading session and ended the day at $5.38. PETX Gross Margin is 11.10% and its has a return on assets of -45.20%. Aratana Therapeutics, Inc. (NASDAQ:PETX) quarterly performance is -69.55%.
Aratana Therapeutics, Inc. (NASDAQ:PETX), announced plans to participate in two upcoming investor events. Aratana join a fireside chat at Piper Jaffray’s 27th Healthcare Conference in New York City on December 1, 2015 at 12 p.m. ET. Additionally, Aratana will present at the Bank of America Merrill Lynch 2015 Animal Health Summit in Boston on December 16, 2015 at 8 a.m. ET.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) caters to the Healthcare space. Its weekly performance is -4.66%. On the last day of trading company shares ended up at $0.43. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance from 50-day simple moving average (SMA50) is -7.70%.
Zacks upgraded shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) from a hold rating to a strong-buy rating in a report issued on Thursday morning, MarketBeat.Com reports. Zacks currently has $0.50 price objective on the biopharmaceutical company’s stock.
Leave a Reply